Outsourced Pharma Capabilities Update October 2026: Viral Vectors

Discover how Vector BioMed’s LENTIVERSE™ platform provides a high-titer toolbox for LV, backed by proprietary technology and expert design for a streamlined approach. Next-generation LV-based products require higher yield with lower impurities, and leading targeted vector technologies, like efficient vector membrane engineering, to activate and stimulate T cell expansion. Supporting in vivo CAR-T clinical development starts with the same pragmatic foundation as other LV-based therapies, i.e., rapid optimization, enhanced function, cost-effective manufacturing, and a path to commercial.

Complete the Form to View Webinar